Safety and Efficacy of Anti–IL-23 Monoclonal Antibody QX004N for Patients With Psoriasis: A Randomized Clinical Trial
1. 系统已在2025-09-08 11:10:18对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
X Li, B Li, D Yang, M Wang, Q Li, N Wang…
JAMA …, 2024
jamanetwork.com
Importance Psoriasis is a chronic, immune-mediated skin disease with an unmet need for biologic treatment options. Objective To assess the safety, pharmacokinetics, and efficacy of QX004N in healthy individuals and patients with moderate to severe plaque psoriasis in China. Design, Setting, and Participants This randomized clinical trial was composed of 2 parts. Part 1 was a first-in-human, single-ascending-dose, phase 1a clinical trial conducted from November 2, 2021, to January 16, 2023. Part 2 was a double-blind, multiple dose …
